Short answer
Definium Therapeutics, Inc. (DFTX) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026.
- Top risk flagged: Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026
FY2025 key financial metrics · XBRL
- Net income
- −$184M
- −69.1% YoY
- EPS (diluted)
- −$2.06
- −33.8% YoY
- ROE
- -55.3%
- −10.3 pp YoY
- Operating cash flow
- −$132M
- −66.3% YoY
Source: XBRL data from the Definium Therapeutics, Inc. (DFTX) FY2025 10-K on SEC EDGAR. USD.
Definium Therapeutics, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: late-stage clinical biopharma developing psychedelics-based treatments for brain health disorders
- New emphasis on Phase 3 trials for DT120 ODT targeting GAD and MDD; initiated DT402 Phase 2a trial for autism spectrum disorder in late 2025
- Strategic shift: rebranded from MindMed to Definium Therapeutics in January 2026, began trading as “DFTX” on Nasdaq
- Quantitative highlight: DT120 Phase 2b GAD trial showed 7.6-point HAM-A improvement vs placebo (p<0.0004) with 65% response rate sustained to 12 weeks
- Noteworthy: FDA granted Breakthrough Therapy designation for DT120 in GAD and UK’s MHRA issued Innovation Passport designation in 2024
Management Discussion & Analysis
- Forward-looking statements mentioned with general risk disclosure but no specific guidance or outlook
Risk Factors
- Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026
- Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses
- Operational risk: Dependence on contract research and manufacturing organizations for clinical trials and cGMP-compliant product supply
- Competitive risk: Psychedelic drug market includes competitors developing alternative therapies for brain health disorders (no named competitor disclosed)
- Financial risk: $411.6M cash as of Dec 31, 2025, expected funding into 2028, but reliance on future equity/debt raises could dilute shareholders or impose restrictive covenants
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.